<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989572</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02101</org_study_id>
    <secondary_id>NCI-2013-02101</secondary_id>
    <secondary_id>CALGB 500101</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>ECOG-4697</secondary_id>
    <secondary_id>CDR0000067568</secondary_id>
    <secondary_id>SWOG-E4697</secondary_id>
    <secondary_id>9546</secondary_id>
    <secondary_id>E4697</secondary_id>
    <secondary_id>E4697</secondary_id>
    <nct_id>NCT01989572</nct_id>
    <nct_alias>NCT00005034</nct_alias>
  </id_info>
  <brief_title>Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With &quot;No Evidence of Disease&quot; After Complete Surgical Resection of &quot;Locally Advanced&quot; and/or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well
      they work compared to sargramostim and vaccine therapy together in preventing disease
      recurrence in patients with melanoma that has been removed by surgery. Sargramostim may
      stimulate the immune system in different ways and stop tumor cells from growing. Vaccines
      made from peptides may help the body build an effective immune response to kill tumor cells.
      It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective
      alone or together in preventing recurrence of melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare overall survival and disease-free survival of patients with completely resected
      stage IV melanoma or stage III melanoma with gross extranodal extension, satellites, and/or
      intransit lesions, treated with granulocyte macrophage colony-stimulating factor (GM-CSF)
      (sargramostim) vs. no GM-CSF, or other high risk patients listed in the eligibility section.

      SECONDARY OBJECTIVES:

      I. To compare, using a 2 x 2 factorial design, overall survival and disease-free survival of
      human leukocyte antigen (HLA)-A2 positive patients treated with peptide vaccination vs. no
      peptide vaccination.

      II. The following descriptive evaluations of survival and disease-free survival are planned
      for the HLA-A2 positive patients: (1) GM-CSF plus peptide vaccination vs. peptide vaccination
      alone; (2) GM-CSF plus peptide vaccination vs. GM-CSF alone; (3) GM-CSF plus peptide
      vaccination vs. placebo.

      III. Survival and disease-free survival of HLA-A2 positive patients not receiving peptide
      vaccination will be compared to that of HLA-A2 negative patients not receiving peptide
      vaccination.

      IV. To determine the influence of GM-CSF on circulating dendritic cell numbers and
      subpopulations in peripheral blood of patients receiving and not receiving GM-CSF.

      V. To determine, in HLA-A2 positive patients, whether immunization with peptides with or
      without GM-CSF elicits a measurable T-cell response as assessed by enzyme-linked
      immunosorbent spot (ELISPOT) and the major histocompatibility complex (MHC) tetramer assay,
      and to determine the functionality of these cells by intracellular cytokine staining.

      OUTLINE: HLA-A2 positive patients are randomized to 1 of 4 treatment regimens (Arms I-IV).
      HLA-A2 negative patients are randomized to 1 of 2 treatment arms (Arms V-VI).

      ARM I: Patients receive sargramostim subcutaneously (SC) on days 1-14 and peptide vaccine
      comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete
      Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2
      and subsequent courses).

      ARM II: Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising
      tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant
      or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent
      courses).

      ARM III: Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either
      incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1
      (course 2 and subsequent courses).

      ARM IV: Patients receive sargramostim placebo SC on days 1-14 and peptide placebo mixed with
      either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and
      day 1 (course 2 and subsequent courses).

      ARM V: Patients receive sargramostim SC on days 1-14.

      ARM VI: Patients receive sargramostim placebo SC on days 1-14.

      In all arms, treatment repeats every 28 days for up to 13 courses in the absence of disease
      progression or unacceptable toxicity.

      In the event of recurrence, patients who undergo complete resection of the recurrence may
      continue treatment for 6 courses or until completion of 1 year of therapy (whichever is
      longer). For patients with recurrence that is not surgically resectable or experiencing
      second recurrence, treatment will be discontinued.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, and then every 12 months for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2000</start_date>
  <completion_date type="Actual">January 31, 2013</completion_date>
  <primary_completion_date type="Actual">October 8, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years,up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival in HLA-A2 Positive Patients</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Overall Survival Rate</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Recurrence Free Survival Rate</measure>
    <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
    <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">815</enrollment>
  <condition>Iris Melanoma</condition>
  <condition>Medium/Large Size Posterior Uveal Melanoma</condition>
  <condition>Mucosal Melanoma</condition>
  <condition>Ocular Melanoma With Extraocular Extension</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Recurrent Uveal Melanoma</condition>
  <condition>Small Size Posterior Uveal Melanoma</condition>
  <condition>Stage IIA Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IIA Uveal Melanoma AJCC v7</condition>
  <condition>Stage IIB Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IIB Uveal Melanoma AJCC v7</condition>
  <condition>Stage IIC Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Uveal Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Uveal Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Uveal Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IV Uveal Melanoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (sargramostim, peptide vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (sargramostim placebo, peptide vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (sargramostim, peptide placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (placebo, peptide placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC on days 1-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI (sargramostim placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive sargramostim placebo SC on days 1-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (sargramostim, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm II (sargramostim placebo, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm III (sargramostim, peptide placebo)</arm_group_label>
    <arm_group_label>Arm IV (placebo, peptide placebo)</arm_group_label>
    <arm_group_label>Arm V (sargramostim)</arm_group_label>
    <arm_group_label>Arm VI (sargramostim placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given GM-CSF placebo SC</description>
    <arm_group_label>Arm II (sargramostim placebo, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm IV (placebo, peptide placebo)</arm_group_label>
    <arm_group_label>Arm VI (sargramostim placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given peptide placebo SC</description>
    <arm_group_label>Arm III (sargramostim, peptide placebo)</arm_group_label>
    <arm_group_label>Arm IV (placebo, peptide placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (sargramostim, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm III (sargramostim, peptide placebo)</arm_group_label>
    <arm_group_label>Arm V (sargramostim)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tyrosinase Peptide</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (sargramostim, peptide vaccine)</arm_group_label>
    <arm_group_label>Arm II (sargramostim placebo, peptide vaccine)</arm_group_label>
    <other_name>Tyrosinase Peptides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have HLA-A2 status known prior to randomization; typing may be obtained
             through a local laboratory facility or through a reference lab utilized by the
             initiating institution; if typing is not available through these means, it may be
             obtained from the University of Pittsburgh

          -  All patients must have disease completely resected with one of the following in order
             to be eligible:

               -  Completely resected disease

               -  Any locoregional recurrence after prior adjuvant interferon or failure on S008

               -  Any local recurrence of disease after adequate surgical excision of the original
                  primary

               -  Mucosal melanoma

               -  Stage IV melanoma (cutaneous, ocular, mucosal, or unknown primary)

          -  The following groups of patients may be entered onto this trial only if they are
             ineligible for S0008 or are, in the opinion of the managing physician, medically unfit
             to receive standard high-dose interferon:

               -  Any clinically evident satellite or in-transit disease

               -  Stage II disease with gross extracapsular extension

               -  Recurrence in a previously resected nodal basin

               -  Four or more involved lymph nodes or matted lymph nodes

               -  Ulcerated primary melanoma and any involved lymph nodes

                    -  NOTE: Patients who are eligible for S0008 will be strongly encouraged to
                       participate in that study in preference to this one

          -  Patients must have been surgically rendered free of disease with negative margins on
             resected specimens; patients rendered free of disease by non-surgical means are not
             eligible

          -  Patients must be randomized within 112 days (16 weeks) of surgical resection; if more
             than one surgical procedure is required to render the patient disease-free, all
             required surgeries must be accomplished within this 16 week time period

          -  Patients must not have received any adjuvant treatment (chemotherapy, biotherapy, or
             limb perfusion) after the resection(s) that make(s) them eligible for this trial; one
             systemic treatment after a prior surgery is allowed, and must have been completed &gt;= 8
             weeks prior to randomization; (when chemotherapy and biotherapy are given together as
             one planned treatment [biochemotherapy], this counts as one regimen); NOTE: Previous
             radiation therapy, including after the resection, is allowed as long as 30 days elapse
             between the radiation and initiation of therapy

          -  Prior treatment with GM-CSF or any peptides used in this protocol, is not allowed

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Patients must not have an active infection requiring treatment with parenteral
             antibiotics

          -  Patients must not have other significant medical, surgical, or psychiatric conditions
             or require any medication or treatment that may interfere with compliance on any of
             the E4697 treatment regimens

          -  Patients must not have a diagnosis or evidence of organic brain syndrome or
             significant impairment of basal cognitive function or any psychiatric disorder that
             might preclude participation in the full protocol

          -  Patients must be able to self-administer or arrange for administration of subcutaneous
             injections

          -  Patients who have other current malignancies are not eligible

          -  Patients with prior history at any time of any in situ cancer, lobular carcinoma of
             the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark
             I melanoma in situ are eligible; patients who meet this criteria must be disease-free
             at time of randomization

          -  Patients with prior history of basal or squamous skin cancer are eligible; patients
             who meet this criteria must be disease-free at time of randomization

          -  Patients who have had multiple primary melanomas are eligible

          -  Patients with other malignancies are eligible if they have been continuously disease
             free for &gt; 5 years prior to the time of randomization

          -  Patients must not have autoimmune disorders, conditions of immunosuppression or
             treatment with systemic corticosteroids, including oral steroids (i.e., prednisone,
             dexamethasone), continuous use of topical steroid creams or ointments, or any steroid
             containing inhalers; replacement doses of steroids for patients with adrenal
             insufficiency are allowed; patients who discontinue use of these classes of medication
             for at least 2 weeks prior to randomization are eligible if, in the judgment of the
             treating physician, the patient is not likely to require these classes of drugs during
             the study

          -  Women of childbearing potential must not be pregnant (negative beta human chorionic
             gonadotropin [bHCG] within 2 weeks prior to randomization) or breast-feeding

          -  Women of childbearing potential and sexually active males must be counseled to use an
             accepted and effective method of contraception (including abstinence) while on
             treatment and for a period of 18 months after completing or discontinuing treatment

          -  All patients must have brain computed tomography (CT) or magnetic resonance imaging
             (MRI), chest CT or chest x-ray (CXR), and abdominal (liver) CT or MRI within 4 weeks
             prior to randomization; positron emission tomography (PET) scans are also acceptable
             in place of CT, CXR and/or abdominal MRI if obtained within 4 weeks prior to
             randomization; patients with lesions on the lower extremity must also have pelvic
             imaging within this time period; this is also strongly recommended for patients with
             lesions on the lower trunk; PET scans are acceptable

          -  Patients with resection of visceral disease must have imaging of the affected
             area/organ documenting disease-free status within 2 weeks prior to randomization

          -  White blood cells (WBC) &gt;= 3,000/mm?

          -  Platelet count &gt;= 100,000/mm?

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =&lt; 2
             x institutional upper limit (IUL) of normal

          -  Bilirubin =&lt; 2 x IUL of normal

          -  Serum creatinine =&lt; 1.8 mg/dl

          -  Alkaline phosphatase and lactate dehydrogenase (LDH) must be performed within 4 weeks
             prior to randomization; LDH must be normal; patients with abnormal alkaline
             phosphatase which is =&lt; 1.25 times the institutional upper limit of normal who have a
             negative CT or MRI of the liver and negative bone scan or a negative PET scan are
             eligible

          -  Patients with bone pain must have a bone scan within 4 weeks prior to randomization to
             document the absence of tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Lawson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile Infirmary Medical Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center-Herrick Campus</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-San Diego Mission</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center -San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration-San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Community Hospital</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCL Health Saint Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital and Regional Medical Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Memorial Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Florida Regional Medical Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health Hollis Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists-West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Army Medical Center</name>
      <address>
        <city>Fort Gordon</city>
        <state>Georgia</state>
        <zip>30905-5650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Georgia Medical Center/Pearlman Cancer Center</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush - Copley Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC - Ames</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center - East Campus</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa-Wide Oncology Research Coalition NCORP</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita NCI Community Oncology Research Program</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health Center-Summa</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Medical Center</name>
      <address>
        <city>Greenfield</city>
        <state>Massachusetts</state>
        <zip>01301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Consortium of West Michigan NCORP</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Health Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic - Hematology/Oncology Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis-Cape Girardeau CCOP</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks NCORP</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Healthcare</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Consortium NCORP</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Saint Francis</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Immanuel Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Adminstration New Jersey Health Care System</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018-1095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Wakefield Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glens Falls Hospital</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Regional Medical Center</name>
      <address>
        <city>Middletown</city>
        <state>New York</state>
        <zip>10940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interlakes Foundation Inc-Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Oncology Research (SCOR) Consortium NCORP</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Barrett Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton NCI Community Oncology Research Program</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma Research</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital-Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's University Hospital-Bethlehem Campus</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware County Memorial Hospital</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary Medical and Regional Cancer Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pottstown Hospital</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group PC-Robert Packer Hospital</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee State University</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37614-0054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont and State Agricultural College</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Memorial Hospital</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Center-Marshfield</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth Oconomowoc Memorial Hospital</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://nctn-data-archive.nci.nih.gov/</url>
    <description>Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was open between December 29, 1999 and October 31, 2006. A total of 815 patients were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
        </group>
        <group group_id="P2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="P3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="P5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="P6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="107"/>
                <participants group_id="P5" count="190"/>
                <participants group_id="P6" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="186"/>
                <participants group_id="P6" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>error</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>maximum dose reached</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown/not specify</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not start protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients regardless of eligibility and treatment status</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
        </group>
        <group group_id="B2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="B3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
        </group>
        <group group_id="B5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="B6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="190"/>
            <count group_id="B6" value="189"/>
            <count group_id="B7" value="815"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="27" upper_limit="83"/>
                    <measurement group_id="B2" value="56" lower_limit="22" upper_limit="82"/>
                    <measurement group_id="B3" value="57" lower_limit="23" upper_limit="87"/>
                    <measurement group_id="B4" value="58" lower_limit="23" upper_limit="82"/>
                    <measurement group_id="B5" value="60" lower_limit="19" upper_limit="88"/>
                    <measurement group_id="B6" value="57" lower_limit="19" upper_limit="87"/>
                    <measurement group_id="B7" value="58" lower_limit="19" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>One patient on arm V had missing data for gender. Hence, a total of 189 patients on arm V reported gender.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="77"/>
                    <measurement group_id="B7" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="112"/>
                    <measurement group_id="B7" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as time from randomization to death from any cause.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Patients received GM-CSF in the trial, including patients on arms I, III, V.</description>
          </group>
          <group group_id="O2">
            <title>GM-CSF Placebo</title>
            <description>Patients who did not receive GM-CSF (ie, received GM-CSF placebo) in the trial, including patients on arms II, IV and VI</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as time from randomization to death from any cause.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="53.4" upper_limit="83.5"/>
                    <measurement group_id="O2" value="59.3" lower_limit="44.4" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.528</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on HLA-A2 status, site of metastases and number of metastatic lesions.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Free Survival</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Patients received GM-CSF in the trial, including patients on arms I, III, V.</description>
          </group>
          <group group_id="O2">
            <title>GM-CSF Placebo</title>
            <description>Patients who did not receive GM-CSF (ie, received GM-CSF placebo) in the trial, including patients on arms II, IV and VI</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="9.4" upper_limit="14.8"/>
                    <measurement group_id="O2" value="8.8" lower_limit="7.5" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on HLA-A2 status, site of metastases, and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</title>
        <description>Overall survival is defined as time from randomization to death from any cause.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years,up to year 15</time_frame>
        <population>all HLA-A2 positive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Vaccination</title>
            <description>Patients who were HLA-A2 positive and received peptide vaccine in the trial, including 109 patients on arm I and 111 patients on arm II.</description>
          </group>
          <group group_id="O2">
            <title>Peptide Placebo</title>
            <description>Patients who were HLA-A2 positive and received peptide placebo in the trial, including 109 patients on arms III and 107 patients on arm IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Human Leukocyte Antigens-A2 (HLA-A2) Positive Patients</title>
          <description>Overall survival is defined as time from randomization to death from any cause.</description>
          <population>all HLA-A2 positive patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="47.0" upper_limit="92.3"/>
                    <measurement group_id="O2" value="63.3" lower_limit="49.2" upper_limit="105.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on GM-CSF, site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Free Survival in HLA-A2 Positive Patients</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all HLA-A2 positive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Peptide Vaccination</title>
            <description>Patients who were HLA-A2 positive and received peptide vaccine in the trial, including 109 patients on arm I and 111 patients on arm II.</description>
          </group>
          <group group_id="O2">
            <title>Peptide Placebo</title>
            <description>Patients who were HLA-A2 positive and received peptide placebo in the trial, including 109 patients on arms III and 107 patients on arm IV</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival in HLA-A2 Positive Patients</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all HLA-A2 positive patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8.7" upper_limit="20.4"/>
                    <measurement group_id="O2" value="9.8" lower_limit="7.7" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>stratifying on GM-CSF, site of metastases and number of metastatic lesions</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Overall Survival Rate</title>
        <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (GM-CSF, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
          </group>
          <group group_id="O3">
            <title>Arm III (GM-CSF, Peptide Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
            <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O5">
            <title>Arm V (GM-CSF)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (GM-CSF Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Overall Survival Rate</title>
          <description>Overall survival is defined as time from randomization to death from any cause, and 5-year overall survival rate is estimated via Kaplan-Meier method.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="45.4" upper_limit="64.5"/>
                    <measurement group_id="O2" value="51.9" lower_limit="42.0" upper_limit="61.0"/>
                    <measurement group_id="O3" value="51.1" lower_limit="41.2" upper_limit="60.1"/>
                    <measurement group_id="O4" value="51.6" lower_limit="41.4" upper_limit="60.9"/>
                    <measurement group_id="O5" value="51.2" lower_limit="43.8" upper_limit="58.2"/>
                    <measurement group_id="O6" value="46.7" lower_limit="39.3" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with positive HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with negative HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Recurrence Free Survival Rate</title>
        <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
        <time_frame>assessed every 3 months if patient is &lt; 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if &gt;5 years, up to year 15</time_frame>
        <population>all randomized patients, regardless of eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (GM-CSF, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide vaccine: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC
GM-CSF placebo: Given SC</description>
          </group>
          <group group_id="O3">
            <title>Arm III (GM-CSF, Peptide Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
            <description>Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC
peptide placebo: Given SC</description>
          </group>
          <group group_id="O5">
            <title>Arm V (GM-CSF)</title>
            <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
          </group>
          <group group_id="O6">
            <title>Arm VI (GM-CSF Placebo)</title>
            <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Recurrence Free Survival Rate</title>
          <description>Recurrence free survival is defined as time from randomization to first disease recurrence or death from any cause (whichever occur first), censoring cases without recurrence or death at the last date of known free of recurrence free survival events, and 5-year overall survival rate is estimated via Kaplan-Meier method. Disease recurrence was determined based on positive cytology or biopsy in the presence of a single new lesion or the appearance of multiple lesions consistent with metastatic disease, or a positive brain CT or MRI scan or CSF cytology.</description>
          <population>all randomized patients, regardless of eligibility</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="23.6" upper_limit="41.5"/>
                    <measurement group_id="O2" value="33.2" lower_limit="24.4" upper_limit="42.2"/>
                    <measurement group_id="O3" value="31.3" lower_limit="22.8" upper_limit="40.2"/>
                    <measurement group_id="O4" value="28.0" lower_limit="19.7" upper_limit="36.9"/>
                    <measurement group_id="O5" value="30.6" lower_limit="24.1" upper_limit="37.3"/>
                    <measurement group_id="O6" value="22.9" lower_limit="17.1" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparison in patients with positive HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment arm comparisons in patients with negative HLA-A2 status</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Log Rank</method>
            <method_desc>stratifying on site of metastases and number of metastatic lesions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every cycle (1 cycle=28 days) for cycles 1, 2, 3, and 4; after cycle 4, assessed every 3 months (at the completion of cycles 7, 10, 13) while on treatment and for 30 days after the end of treatment</time_frame>
      <desc>After off treatment, if the patient experienced any clinical problems possibly related to the protocol treatment, the clinical problems were also reported per the standard ECOG follow-up schedule: every 3 months if patient is &lt;2 years from study entry, every 6 months if patient is 2-5 years from study entry, and every 12 months if &gt;5 years.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (GM-CSF, Peptide Vaccine)</title>
          <description>Arm I (GM-CSF, peptide vaccine) Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC peptide vaccine: Given SC</description>
        </group>
        <group group_id="E2">
          <title>Arm II (GM-CSF Placebo, Peptide Vaccine)</title>
          <description>Arm II (GM-CSF placebo, peptide vaccine) Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
peptide vaccine: Given SC GM-CSF placebo: Given SC</description>
        </group>
        <group group_id="E3">
          <title>Arm III (GM-CSF, Peptide Placebo)</title>
          <description>Arm III (GM-CSF, peptide placebo) Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
sargramostim: Given SC peptide placebo: Given SC</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (GM-CSF Placebo, Peptide Placebo)</title>
          <description>Arm IV (GM-CSF placebo, peptide placebo) Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
GM-CSF placebo: Given SC peptide placebo: Given SC</description>
        </group>
        <group group_id="E5">
          <title>Arm V (GM-CSF)</title>
          <description>Patients receive GM-CSF (sargramostim) SC on days 1-14.
sargramostim: Given SC</description>
        </group>
        <group group_id="E6">
          <title>Arm VI (GM-CSF Placebo)</title>
          <description>Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
GM-CSF placebo: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection with grade 3 or 4 neutropenia</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection with unknown ANC</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, spe</sub_title>
                <description>infection w/o neutropenia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue di</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specif</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="180" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="143" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>General disorders and administration sit</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders -</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

